| TITLE |
Broadcast Date |
| Updates in the Management of Alopecia Areata |
April 14, 2023 |
| Beyond the Interaction Checker: A Deep Dive on Non-Traditional Drug Interactions with Immune Checkpoint Inhibitors |
April 5, 2023 |
| Pharmacy Technician Development: Advancing the Career Trajectory |
March 31, 2023 |
| Can’t Touch This! Minimizing Hazardous Drug Exposures Across the Institution |
March 27, 2023 |
Models for Pharmacy Technician Training Programs
|
February 24, 2023 |
Turn the Page for New Perspectives on USP Chapter 800
|
February 3, 2023 |
| New Year, New Subvariants - COVID Therapeutics in 2023 |
January 27, 2023 |
| Prioritizing Prickly Pain Policy |
January 20, 2023 |
| Boosters, Biologics, Antivirals - Oh My! - COVID-19 in the Immunocompromised |
October 28, 2022 |
| Keeping Pace with the Guidelines. C diff Past, Present, and Future |
October 8, 2022 |
| Accelerating Biosimilar Adoption: Conversation with the Experts |
August 19, 2022 |
| Standardize for Safety: The Role and Reflections of the Pharmacy Technician |
July 29, 2022 |
| Standardize 4 Safety: Taking Aim at Strategies for Adoption |
June 24, 2022 |
| Standardize 4 Safety - Past, Present, and Future of Safer Care |
May 23, 2022 |
| Don’t Skip a Beat: Practical Considerations When Choosing an Anticoagulant for Nonvalvular Atrial Fibrillation |
May 20, 2022 |
| Finding Hidden Stroke Risk: Screening for Atrial Fibrillation |
April 29, 2022 |
| Reflections on Implementation of Central Fill |
April 22, 2022 |
| Where Do We Go from Here? Discussing the Future of Eosinophilic Esophagitis Treatment |
March 25, 2022 |
| Conversation with an Anesthesiologist: Key Issues on Neuromuscular Monitoring and Neuromuscular Blockade Reversal Strategies |
March 15, 2022 |
| Pharmacist Education on Immunotherapy: An Investment into the Patient as a Team Member in irAE Management |
February 25, 2022 |
| Eosinophilic Esophagitis: The Role of Allergy Testing and Dietary Interventions |
February 18, 2022 |
| Reverse to Go Forward: Monitoring and Cost Considerations for Reversing Neuromuscular Blockade |
February 15, 2022 |
| irAE Potpourri: A Little Bit of This and That for Anyone and Everyone |
January 28, 2022 |
| Controlled Substances Diversion: Creating a Value Proposition for All |
January 26, 2022 |
| C. diff Infection: What you need to know! |
November 17, 2021 |
| One Health System’s Experience with Insourcing |
October 8, 2021 |
| Is Insourcing of Compounded Sterile Preparations Right for My Organization? |
September 29, 2021 |
| Immune Checkpoint Inhibitors in Cancer Treatment: Overcoming Challenges in Identifying and Managing Immune-related Adverse Events |
September 15, 2021 |
| COVID-19 Chat with the Experts: Remdesivir and Supportive Care in Patients with COVID-19 |
July 19, 2021 |
| VTE Prophylaxis in the Medically Ill: Extending the Conversation, Part 3 |
May 12, 2021 |
| DOAC-Related Bleeding Reversed, Now What? |
May 6, 2021 |
| Official Cardiovascular Support for Updating your iPAD (interest in Peripheral Arterial Disease): Clinical Trial Data |
April 29, 2021 |
| VTE Prophylaxis in the Medically Ill: Extending the Conversation, Part 2 |
April 29, 2021 |
| VTE Prophylaxis in the Medically Ill: Extending the Conversation, Part 1 |
April 21, 2021 |
| Continuing the Dialogue: Clinical Conversations on Neuromuscular Blockade and Reversal Strategies |
April 20, 2021 |
| Official Cardiovascular Support for Updating your iPAD (interest in Peripheral Arterial Disease): Risk Factor Management |
April 15, 2021 |
| To Reverse, or Not to Reverse (the Bleed), That Is the Question |
April 8, 2021 |
| Official Cardiovascular Support for Updating your iPAD (interest in Peripheral Arterial Disease): Screening and Pathophysiology |
April 8, 2021 |
| Microbiome 101: Healthy Bugs Make Healthy Bodies |
April 1, 2021 |
| C.diff Therapeutics |
April 1, 2021 |
| Microbiome 101: Healthy Bugs Make Healthy Bodies |
April 1, 2021 |
| Pharmacy Hot Topics: Clinical Conversations on Neuromuscular Blockade and Reversal Strategies |
February 16, 2021 |
| Best Practice in Formulary Management: Biosimilar Reimbursement Challenges |
December 15, 2020 |
| Best Practice in Formulary Management: Keeping Patients Safe From White Bagging |
November 25, 2020 |
| Best Practice in Formulary Management: Integrating Biosimilars Into Your IT Systems |
November 3, 2020 |
| Making the Most of Technology When Managing Type 2 Diabetes |
|
| Best Practices in Formulary Management Unique Strategies for Biosimilar Adoption |
September 29, 2020 |
| Getting to the Bottom of Hypoglycemia: The Fear is Real |
|
| Treating Lung Cancer and Melanoma with Immune Checkpoint Inhibitors |
|
| Employing Best Practices to Prevent, Treat, and Eliminate Clostridioides difficile Infection Recurrences |
|
| Managing Patients with COPD: Continuing the Conversation |
|
| Managing Patients with COPD: An Interprofessional Team Discussion |
|
| Revised USP Chapter 797 (Part 3): Practical Approaches to Attaining Compliance |
|
| Revised USP Chapter 797 (Part 2): Getting Your Facility Ready |
|
| Revised USP Chapter (Part 1): Overview of Changes |
|
| Integrating Gene Therapies into Pharmacy Practice |
|
